Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SRXN1 pseudogene 2 (SRXN1P2) is a genomic pseudogene derived from the Sulfiredoxin 1 (SRXN1) gene. Unlike its parent gene SRXN1, which encodes an oxidoreductase involved in the reduction of over-oxidized peroxiredoxins and resistance to oxidative stress[1][2], SRXN1P2 does not encode a functional protein and is not implicated in disease or therapeutic applications. There is no evidence supporting a physiological role for SRXN1P2, and it is not included in clinical or molecular target databases. If the intent was to refer to the bona fide gene *Sulfiredoxin 1* (SRXN1, not SRXN1P2), this gene is an established antioxidant enzyme and is implicated in oxidative stress responses and several disease contexts, including cancer and inflammatory conditions[1][2][3]. However, *SRXN1 pseudogene 2* is not a target in any therapeutic or biomarker context. If you require information on the functional gene (SRXN1), please clarify your request.
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SRXN1 pseudogene 2 (SRXN1P2).